TAIRA Yusuke

写真a

Researcher Number(JSPS Kakenhi)

00889412

Research Areas 【 display / non-display

  • Life Science / Obstetrics and gynecology

Published Papers 【 display / non-display

  • A high-risk gestational trophoblastic neoplasia derived from a complete hydatidiform mole with coexisting fetus identified by short tandem repeats analysis: A case report.

    Taira Y, Shimoji Y, Nakasone T, Arakaki Y, Nakamoto T, Kinjo T, Kudaka W, Mekaru K, Aoki Y

    Case reports in women's health ( Case Reports in Women's Health )  31   e00336   2021.07 [ Peer Review Accepted ]

    Type of publication: Research paper (other science council materials etc.)

     View Summary

    A complete hydatidiform mole coexisting with a fetus (CHMCF) is a rare form of twin pregnancy. High-risk gestational trophoblastic neoplasia (GTN) can occur after a CHMCF pregnancy, although the frequency is low. In cases of GTN, the clinical diagnosis and that based on the International Federation of Gynecology and Obstetrics (FIGO) scoring system can differ. This case report concerns a patient with a choriocarcinoma that was initially diagnosed and treated as a low-risk stage III GTN following a live birth from a CHMCF pregnancy. We used short tandem repeat (STR) analysis to identify the causative pregnancy as the patient's earlier complete hydatidiform mole. Clinicians should anticipate a high-risk GTN when treating persistent trophoblastic disease (PTD) in patients with a non-typical course.

  • A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.

    Taira Y, Shimoji Y, Nakasone T, Arakaki Y, Nakamoto T, Kudaka W, Aoki Y

    The journal of obstetrics and gynaecology research ( Journal of Obstetrics and Gynaecology Research )  47 ( 2 ) 833 - 837   2021.02 [ Peer Review Accepted ]

    Type of publication: Research paper (other science council materials etc.)

     View Summary

    Nasal septal perforation caused by bevacizumab is rarely reported in other cancers such as ovarian cancer and breast cancer, but it has not been reported in cervical cancer. A 48-year-old woman with a medical history of chronic allergic rhinitis was diagnosed stage 4B (T2bN1M0) cervical cancer and paclitaxel and carboplatin along with bevacizumab (triweekly) were administered. After eight courses of chemotherapy, nasal septal perforation was noted. The possibility of nasal septal perforation by bevacizumab was considered by excluding other causes. We report the first case of nasal septal perforation caused by bevacizumab for advanced cervical cancer.

  • Usefulness of separately evaluating lymphatic and venous vessel invasion in cervical adenocarcinoma

    Yusuke Taira, Yuko Shimoji, Tadaharu Nakasone, Yoshihisa Arakaki, Tomoko Nakamoto, Takuma Ooyama, Wataru Kudaka, Itomi Kaneshima, Kumiko Nishihira, Yoichi Aoki

    Ryukyu Medical Journal   39   21 - 28   2020.10 [ Peer Review Accepted ]

    Type of publication: Research paper (other science council materials etc.)

  • Relative dose intensity and overall treatment time in older patients with cervical cancer treated with concurrent chemoradiotherapy.

    Nakamura R, Shimoji Y, Nakasone T, Taira Y, Arakaki Y, Nakamoto T, Ooyama T, Kudaka W, Mekaru K, Aoki Y

    Journal of geriatric oncology ( Journal of Geriatric Oncology )  12 ( 2 ) 332 - 334   2020.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

  • Long-term Outcomes of Cervical Adenocarcinoma Treated With Concurrent Chemoradiotherapy Using Paclitaxel and Cisplatin.

    Arakaki Y, Ariga T, Heianna J, Shimoji Y, Nakasone T, Taira Y, Nakamoto T, Ooyama T, Kudaka W, Kaneshima I, Nishihira K, Mekaru K, Aoki Y

    In vivo (Athens, Greece) ( In vivo (Athens, Greece) )  34 ( 5 ) 2739 - 2743   2020.09 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

     View Summary

    © 2020 International Institute of Anticancer Research. All rights reserved. Background/Aim: We retrospectively analyzed the locally advanced adenocarcinoma (AC)/adenosquamous carcinoma (ASC) of the uterine cervix treated with concurrent chemoradiotherapy using cisplatin plus paclitaxel (TP-CCRT). Patients and Methods: Thirty patients with stage IB-IVA AC/ASC were treated with whole pelvis external beam radiotherapy. A high-dose-rate intracavitary brachytherapy was delivered once per week at a fractional dose of 6 Gy. For TP-CCRT, the patients received cisplatin and paclitaxel. Results: A complete response was achieved in 17 patients (77.3%) in the TP-CCRT group and 4 patients (50.0%) in the P-CCRT group. The 5-year OS rate in the TPCCRT and P-CCRT groups was 74.2% and 25.0% (p=0.0094), the central DFS rate was 58.0% and 12.5% (p=0.0267), and the distant DFS rate was 63.6% and 12.5% (p=0.0042), respectively. Conclusion: TP-CCRT achieves a considerably better disease control for AC of the cervix, leading to a better OS.

display all >>

SDGs 【 display / non-display

  • 婦人科腫瘍